2024 SABCS
2024年圣安东尼奥乳腺癌学术研讨会（SABCS）将于2024年12月10至13日在美国德克萨斯州圣安东尼奥举行。SABCS官网已披露入选本次大会的摘要标题，医脉通小编为您汇总大会相关信息，精选中国专家报告内容，往期传送：
本期将继续为读者带来Poster Session 3（壁报展示3）部分，医脉通与您携手领略中国专家风采！
医脉通小编与您相约圣安东尼奥Henry B. Gonzalez会议中心（地址：900 E. Market Street, San Antonio, TX 78205 USA），为您带来一手资讯！敬请关注医脉通乳腺肿瘤，共享乳腺癌领域最新进展！
Henry B. Gonzalez Convention Center
中国专家壁报展示专场日期及时间一览，跟随医脉通，共享学术盛宴！
Poster Sessions时间轴
Poster Session 3
壁报展示3
当地时间：2024/12/12 12:30-14:00
北京时间：2024/12/13 2:30-4:00
位置：Halls 2-3
01
P3-01-19
Proteomics-based degradome analysis of mammary tumor adjacent adipocyte reveals adipocyte-derived peptide MASP6 promotes breast cancer cell invasion and migration
基于蛋白质组学的乳腺肿瘤邻近脂肪细胞降解组分析显示脂肪细胞衍生肽MASP6促进乳腺癌细胞侵袭和迁移
报告人：Shuhan Zhao
02
P3-02-05
Mitochondrial Metabolism-Related Features Guiding Precision Subtyping and Prognosis in Breast Cancer, Revealing FADS2 as a Novel Therapeutic Target
线粒体代谢相关特征指导乳腺癌的精确亚型分型和预后，揭示FADS2作为一种新的治疗靶点
报告人：Yangyang Cui
03
P3-02-17
tRF-1432–a novel target for reversing chemoresistance in breast cancer
tRF-1432-逆转乳腺癌耐药性的新靶点
报告人：Yuhan Dai
04
P3-02-22
The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance
环状RNA在三阴性乳腺癌和化疗耐药中的作用
报告人：Xiyin Wang
05
P3-02-26
Sex-biased cancer cells induce endocrine therapy resistance and immune suppression in male breast cancer
性别偏倚的癌细胞诱导男性乳腺癌的内分泌治疗耐药和免疫抑制
报告人：Yulin Li
06
P3-02-29
The mechanism of acidic microenvironment promotes tumor-associated macrophages secreting glutamine to activate dual signaling pathways of mTORC1 and c-MYC in CDK4/6 inhibitor resistance of ER-positive breast cancer
酸性微环境机制促进肿瘤相关巨噬细胞分泌谷氨酰胺激活ER阳性乳腺癌CDK4/6抑制剂耐药的mTORC1和c-MYC双信号通路
报告人：Fanli Qu
07
P3-03-15
Racial differences in incidence of depression, anxiety, and insomnia among breast cancer patients on endocrine therapy
接受内分泌治疗的乳腺癌患者抑郁、焦虑和失眠发生率的种族差异
报告人：Shuwen Lin
08
P3-03-17
Genetic Profiles and Precision Medicine in Adolescent and Young Adult Chinese Women with Breast Cancer: A Comprehensive Study
中国青少年和年轻成年乳腺癌女性的遗传谱和精准医学：一项综合研究
报告人：Chengyi Wang, Qing Hao
09
P3-04-06
Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer
BRCA突变载体组织的基因组和转录组学分析揭示了BRCA1/2相关乳腺癌的早期发病机制
报告人：Zuen Ren
10
P3-04-22
An organoid model derived from a patient with breast angiosarcoma
来自一名乳腺血管肉瘤患者的类器官模型
报告人：Xiaoling Liu
11
P3-04-27
Resistance to neratinib in HER2+ breast cancer: Mechanistic insights and treatment approaches
HER2+乳腺癌对奈拉替尼的耐药性：机制见解和治疗方法
报告人：Fu-Tien Liao
12
P3-05-22
Prognostic Significance of Tumor-informed Personalised Circulating Tumor DNA Monitoring in Breast Cancer Patients Undergoing Neoadjuvant Therapy
肿瘤知情个体化循环肿瘤DNA监测对接受新辅助治疗的乳腺癌患者的预后意义
报告人：Yunjiang Liu
13
P3-06-15
Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial
乳腺癌减肥（BWEL）试验中乳腺癌幸存者每日步数的轨迹
报告人：Chao Cao
14
P3-06-16
Heterogeneity of Tertiary Lymphoid Structures Predicts the Response to Neoadjuvant Therapy and Immune Microenvironment Characteristics in Triple-Negative Breast Cancer
三级淋巴结构的异质性可预测三阴性乳腺癌对新辅助治疗的反应和免疫微环境特征
报告人：宋传贵
15
P3-06-17
IAPP mediated anti-breast cancer function of CD8+T cells via targeting cuproptosis
IAPP通过靶向cuproptosis介导CD8+T细胞的抗乳腺癌功能
报告人：Zhijian Huang
16
P3-06-30
Novel Humanized LIV-1 Antibody Based ADCs Conjugated with Topoisomerase I Inhibitor Payloads Displayed Significantly Higher Anti-tumor Activities than MMAE based ADCs in TNBC Tumor Models
在TNBC肿瘤模型中，与拓扑异构酶I抑制剂有效载荷偶联的新型基于人源化LIV-1抗体的ADC显示出比基于MMAE的ADC显着更高的抗肿瘤活性
报告人：Xueming Qian
17
P3-07-04
Postoperative upper Limb Edema & Dysfunction Generated by axillary nodes Excision w/ or w/out axillary vein branches reservation in breast cancer patients (PLEDGE-Surgery):a prospective,multiple-center,double-blinded, randomized controlled study
术后上肢水肿和功能障碍由腋窝淋巴结产生切除乳腺癌患者的腋静脉分支保留（PLEDGE-手术）：一项前瞻性，多中心，双盲，随机对照研究
报告人：Qianrui Xu
18
P3-07-21
Transcriptomic analysis of the tumor immune microenvironment (TIME) in patients with breast cancer with liver metastasis (BCLM)
肝转移乳腺癌患者肿瘤免疫微环境（TIME）的转录组学分析（BCLM）
报告人：Jiayi Tan
19
P3-07-24
Real-World Treatment Patterns and Clinical Outcomes of Sacituzumab Govitecan in HER2 negative metastatic breast cancer patients in China
戈沙妥珠单抗在中国HER2阴性转移性乳腺癌患者中的真实世界治疗模式和临床结果
报告人：Huanhuan Zhou
20
P3-07-30
Mesenchymal Stem Cells Regulate E-cadherin Level, Proliferation, and Immuno-Resistance on Breast Cancer Cells
间充质干细胞调节乳腺癌细胞的E-钙粘蛋白水平、增殖和免疫抵抗
报告人：Bei Dai
21
P3-08-14
Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in 737 Patients with Breast Cancer Bone Metastasis: A Retrospective Study from China
737例乳腺癌骨转移患者骨转移发生时间及疾病治疗模式分析——来自中国的回顾性研究
报告人：王晓稼
22
P3-08-30
Development of humanized anti-FABP4 monoclonal antibodies for potential treatment of breast cancer
开发人源化抗FABP4单克隆抗体用于乳腺癌的潜在治疗
报告人：Bing Li
23
P3-09-11
Effect of Removed Lymph Nodes Number on Survival in Node-negative Early Breast Cancer: A Multicenter Retrospective Study (CSOBO YOUNG-03)
淋巴结数量切除对淋巴结阴性早期乳腺癌生存率的影响：一项多中心回顾性研究（CSOBOYOUNG-03）
报告人：余科达
24
P3-10-13
A Comprehensive Analysis of Dysregulation in the PTEN/PI3K/AKT Pathway in Breast Cancer Among the Chinese Population
中国人群乳腺癌PTEN/PI3K/AKT通路失调的综合分析
报告人：Ziang Li
25
P3-10-23
RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer: APRIL Trial
RecurIndex预测早期管腔乳腺癌的复发风险：APRIL试验
报告人：Lei Lei
26
P3-11-12
(Neo)adjuvant Therapy Patterns and Outcomes in Patients with HR-Positive/HER2-Positive Early or Locally Advanced Breast Cancer: a Real-World Study Using National Cancer Information Database, China
HR-Positive/HER2阳性早期或局部晚期乳腺癌患者的（新）辅助治疗模式和结果：一项使用中国国家癌症信息数据库的真实世界研究
报告人：刘真真
27
P3-11-14
Differential response to neoadjuvant antiHER2 therapy between HER2 2+ISH+ and HER2 3+ in HER2-positive breast cancer: Is HER2 2+ISH+ a distinct subtype?
HER2阳性乳腺癌中HER2 2+ISH+ 和 HER2 3+ 对新辅助抗HER2治疗的不同反应：HER2 2+ISH+ 是一种独特的亚型吗？
报告人：Lingjun Ma
28
P3-11-16
Personalized Neoadjuvant Therapy Guided by Drug Screening of Patient-Derived Tumor-Like Cell Clusters in HER2-Positive Breast Cancer: A Prospective Phase II Study and Exploratory Analysis
HER2阳性乳腺癌中患者来源的肿瘤样细胞簇药物筛选指导的个性化新辅助治疗：一项前瞻性II期研究和探索性分析
报告人：Yaqian Xu
29
P3-11-19
Efficacy of different neoadjuvant systemic treatment regimens in Chinese patients with HER2-positive advanced breast cancer: a real-world retrospective multi-center cohort study
中国HER2阳性晚期乳腺癌患者不同新辅助全身治疗方案的疗效：一项真实世界回顾性多中心队列研究
报告人：Xiaoming Zha
30
P3-11-24
Neoadjuvant Nab-paclitaxel combined with Trastuzumab and Pyrotinib for HER2-enriched subtype of HER2-positive early or locally advanced breast cancer: A multicenter, single-arm, phase 2 trial
新辅助白蛋白结合型紫杉醇联合曲妥珠单抗和吡咯替尼治疗HER2阳性早期或局部晚期乳腺癌的HER2富集亚型：一项多中心、单臂、II期试验
报告人：Wenbin Zhou
31
P3-11-26
A Phase II study of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer
达尔西利联合来曲唑、帕妥珠单抗和曲妥珠单抗作为HR+/HER2+乳腺癌新辅助治疗的II期研究
报告人：Xiaohua Zeng, Xinrui Liang
32
P3-12-03
Optimizing Treatment Sequence for Inoperable LABC: Long-Term Outcomes of Surgery First vs. Neoadjuvant Chemotherapy in a Real-World Setting
优化无法手术的LABC的治疗顺序：在真实世界环境中首先手术与新辅助化疗的长期结果
报告人：Yu Song
33
P3-12-09
Evaluation of the Early Risk of Recurrence in HR+/HER2- Early Breast Cancer Patients – A Retrospective Study Based on the Chinese National Cancer Database
HR+/HER2-早期乳腺癌患者早期复发风险的评价——一项基于中国国家癌症数据库的回顾性研究
报告人：Qiao Li
34
P3-12-22
Neoadjuvant Therapy with Pyrotinib, Subcutaneous Trastuzumab, and Capecitabine for HER2-Positive Early Breast Cancer: A Prospective, Single-Arm, Multicenter Trial
吡咯替尼、皮下注射曲妥珠单抗和卡培他滨治疗HER2阳性早期乳腺癌的新辅助治疗：一项前瞻性、单臂、多中心试验
报告人：LiNa Zhang
备注：排名不分先后，按照摘要号进行排序。本文内容基于SABCS官网发布的信息整理，因目前壁报部分未公布报告者单位，信息可能有遗漏或错误，欢迎留言告知。
编辑：KIKI
审校：Uni/Ryland
排版：KIKI
执行：Squid
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
